ScripAs Donald Trump’s threats to impose tariffs on imported pharmaceuticals increase in intensity, the US president will be pleased to hear that Novartis is expanding its manufacturing and R&D footp
ScripMerger-and-acquisition activity in the biopharmaceutical sector had almost nowhere to go but up in the first quarter of 2025, following a historically low quarter in terms of total potential deal valu
ScripAccording to a new report from the Institute for Clinical and Economic Review (ICER) on the affordability of obesity drugs, compounding is not likely to be a solution to concerns about access and affo
Pink SheetA review of current and year-ago coverage policies for GLP-1 drugs in Medicare and Medicaid suggests the Trump Administration’s decision not to continue with a proposal to require coverage of them may